SAN DIEGO, July 31, 2017 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that the
Company will release its second quarter 2017 financial results and
provide a corporate update on Monday, August
7, 2017, after the close of the U.S. financial
markets. The Company will host a conference call and live
webcast with the investment community the same day at 4:30 p.m. ET.
Conference Call & Webcast Information
When: August 7, 2017, 4:30 p.m. ET
Dial-in: (877) 643-7155 (United
States) or (914) 495-8552 (International)
Conference ID: 60106084
Please join the conference call at least 10 minutes early to
register. You can access the live webcast under the investor
relations section of Arena's website at:
www.arenapharm.com. A replay of the conference call will be
archived under the investor relations section of Arena's website
for 30 days after the call.
About Arena Pharmaceuticals
Arena Pharmaceuticals is a biopharmaceutical company focused on
developing novel, small molecule drugs with optimized receptor
pharmacology designed to deliver broad clinical utility across
multiple therapeutic areas. Our proprietary pipeline includes
potentially first- or best-in-class programs for which we own
global commercial rights. Our three most advanced
investigational clinical programs are ralinepag (APD811) which has
completed a Phase 2 trial for pulmonary arterial hypertension
(PAH), etrasimod (APD334) in Phase 2 evaluation for multiple
autoimmune indications including ulcerative colitis (UC), and
APD371 in Phase 2 evaluation for the treatment of pain associated
with Crohn's disease. In addition, Arena has collaborations with
the following pharmaceutical companies: Eisai Co., Ltd. and Eisai
Inc. (commercial stage), Axovant Sciences (Phase 2 candidate), and
Boehringer Ingelheim International GmbH (preclinical
candidate).
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. Such
forward-looking statements include statements about Arena's focus,
and the potential of its programs and collaborations. For
such statements, Arena claims the protection of the Private
Securities Litigation Reform Act of 1995. Actual events or results
may differ materially from Arena's expectations. Factors that could
cause actual results to differ materially from the forward-looking
statements include those disclosed in Arena's filings with the
Securities and Exchange Commission. These forward-looking
statements represent Arena's judgment as of the time of this
release. Arena disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Corporate Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original
content:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-release-second-quarter-2017-financial-results-and-provide-corporate-update-on-monday-august-7-2017-300496857.html
SOURCE Arena Pharmaceuticals, Inc.